Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis

Linda C Hemphill

doi:10.1016/j.jacl.2010.08.013

Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis

J Clin Lipidol. 2010 Sep-Oct;4(5):346-9. doi: 10.1016/j.jacl.2010.08.013. Epub 2010 Aug 20.

Author

Linda C Hemphill¹

Affiliation

¹ Cardiology Department, Massachusetts General Hospital, Yawkey Center, Suite 5800, 55 Fruit Street, Boston, MA 02114, USA. lhemphill@partners.org

PMID: 21122676
DOI: 10.1016/j.jacl.2010.08.013

Abstract

Options for treatment of severe heterozygous and homozygous familial hypercholesterolemia prior to the statin era were limited by significant side effects and morbidity. The advent of both the statins and technology for the selective removal of LDL via apheresis have revolutionized management but challenges remain.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anticholesteremic Agents / therapeutic use
Azetidines / therapeutic use
Blood Component Removal*
Ezetimibe
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hyperlipoproteinemia Type II / drug therapy
Hyperlipoproteinemia Type II / therapy*
Lipoproteins, LDL / blood*
Patient Selection
Receptors, LDL / genetics

Substances

Anticholesteremic Agents
Azetidines
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoproteins, LDL
Receptors, LDL
Ezetimibe